Kamada Ltd (id:8243 KMDA)
6.05 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 10:58:18 AM)
Exchange open, closes in 5 hours 1 minutes
About Kamada Ltd
Market Capitalization 354.24M
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Headquarters (address) |
2 Holzman Street Rehovot 7670402 Israel |
Phone | 972 8 940 6472 |
Website | https://www.kamada.com |
Employees | 378 |
Sector | Healthcare |
Industry | Drug Manufacturers Specialty & Generic |
Ticker | KMDA |
Exchange | NASDAQ Stock Exchange |
Currency | USD |
52 week range | 4.74 - 6.53 |
Market Capitalization | 354.24M |
Dividend yield forward | 3.00 % |
Dividend yield forward Israel (ID:92, base:19) | 15.67 % |
P/E trailing | 21.89 |
P/E forward | 19.06 |
Price/Sale | 2.29 |
Price/Book | 1.39 |
Beta | 3.00 |
EPS | 3.00 |
EPS Israel (ID:92, base:52) | 3.00 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Kamada Ltd has raised their dividend 3.00 years in a row. This is below the 42132.547600 year average in the 'Drug Manufacturers Specialty & Generic' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Kamada Ltd has raised their dividend 3.00 years in a row. This is below the 42132.547600 year average in the 'Drug Manufacturers Specialty & Generic' industry